CDT (CDT Equity) Tax Expense: $0.00 Mil (TTM As of Dec. 2025)


CDT CDT Equity Inc CDT
10 GF Score
Price $0.62
! 5 Warning Signs
View Full Analysis

What is CDT Equity Tax Expense?

CDT Equity CDT -12.38% 10 Tax Expense is $0.00 Mil as of Dec. 2025. GuruFocus rates CDT with a GF Score™ of 10/100. The stock has 5 warning signs investors should review.

CDT Equity's tax expense for the months ended in Dec. 2025 was $0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.


CDT Equity  (NAS:CDT) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


CDT Equity Tax Expense Related Terms


CDT Equity Tax Expense Historical Data

* Premium members only.

The historical data trend for CDT Equity's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CDT Equity Tax Expense Chart

CDT Equity Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Tax Expense
0.00 0.00 0.00 0.00 0.00

CDT Equity Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CDT
10GF Score
CDT Equity Inc CDT
Tax Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CDT Equity Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of $0.00 Mil mean?
CDT Equity (CDT) has a Tax Expense of $0.00 Mil as of Dec. 2025. Tax expense is the amount of tax the company pays in an accounting period. View historical data on CDT Equity and its competitors.
Is CDT Equity's Tax Expense too high?
CDT Equity's current Tax Expense is $0.00 Mil. Overall, CDT Equity has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does CDT Equity's Tax Expense compare to PULM and ADIL?
CDT Equity's Tax Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Biotechnology company?
A good Tax Expense depends on the Biotechnology industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on CDT Equity and its competitors. CDT Equity's current Tax Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CDT Equity stock overvalued right now?
CDT Equity (CDT) has a current Tax Expense of $0.00 Mil. The current Tax Expense is $0.00 Mil. CDT Equity's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For CDT Equity (CDT), the current Tax Expense is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CDT Equity Business Description

Address 4581 Tamiami Trail North, Suite 200, Naples, FL, USA, 34103
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
10GF Score

Get the complete analysis for CDT

Tax Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.62
Price